Rare types of helper T cells uncovered
Researchers have created a new T cell atlas which could aid the development of novel drug therapies for immune-mediated diseases.
List view / Grid view
Researchers have created a new T cell atlas which could aid the development of novel drug therapies for immune-mediated diseases.
20 June 2024 | By Eurofins DiscoverX
Join this webinar to discover how GPCR functional, cell-based assays determine off-target effects, reveal safety issues, and define drug mechanism of action to ultimately evaluate the therapeutic potential of candidate molecules.
The novel drug, ETD001, could provide an improved approach for mucus clearance in cystic fibrosis patients.
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
The future of liquid biopsy is poised to revolutionise medical diagnostics and treatment. Explore the latest advancements and future prospects of liquid biopsy in our comprehensive eBook.
As antimicrobial resistance continues to advance, novel therapeutics are needed that stop infection and do not contribute to resistance. Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections. Recce’s lead candidate, RECCE® 327 (R327), is a…
Dr H. Rachel Lagiakos is a Senior Principal Scientist in the Therapeutics Group at Schrödinger which she joined in 2018. She completed her PhD in Synthetic Organic Chemistry at Monash University and began her medicinal chemistry career at Cancer Therapeutics (CTx) in Melbourne, Australia in 2012. At CTx, Rachel’s contributions…
In this episode, we explore our understanding of DNA and its implications for health outcomes. Additionally, we discuss the transition from DNA sequencing to actionable insights in medicine, contrasting genetics-driven drug discovery with traditional methods. Finally, we examine the evolving landscape of genetic technology and its potential impact on the…
A novel drug, JHU083, turns into its active, glutamine-blocking form inside tumours, shrinking prostate and bladder cancers in mice.
Neuroscientists are increasingly viewing disorders of the brain through the lens of the underlying molecular mechanisms as sometimes illuminated by genetic variants, rather than classifying disorders based solely on the clinical symptoms. The next step in the evolution of antiseizure medication will likely come from studying these molecular determinants of…
In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches.
In this Q&A, Dr DaeYong Lee discusses how a new method for building up natural immune response could lead to new immunotherapy drugs with safer toxicity profiles.
Download this report now to access exclusive content on innovative cancer treatments, regenerative medicine, gene therapy, and expert insights from leading professionals in the field.
Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific founders and an expert in drug resistance in cancer therapy. She is a biomedical scientist and biochemist by training (University of Fribourg and ETH Zurich, Switzerland) and holds a PhD in Molecular and Translational Biomedicine from ETH Zurich. She led…
As we move towards more generalised AI models, neural networks and natural language interfaces, we’re starting to see machine learning take the place of higher order reasoning and data analysis “sense making.” Traditional scientific inquiry has typically been about asking specific questions of a specific model system under specific conditions.…